

InnoCan Pharma

08:35 23 Oct 2020

Innocan Pharma announces publication of two scientific articles supporting its CLX therapy for COVID-19-infected lungs

Innocan Pharma Corporation (CSE:INNO) (FRA:IP4) announced Friday the recent publication of two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19.

The company said the first paper entitled "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients", was published in the Journal of Stem Cell Research & Therapy on October 15. It outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19.

Specifically, Innocan said the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

The second paper entitled "Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome" was published in the Journal of Cellular and Molecular Medicine on October 15.

It demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

The company said that Innocan Israel, a wholly-owned subsidiary, together with Tel Aviv University Professor Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Innocan said that through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus's direct damage and its cytokine storm. This product is planned to act as a "guided missile" to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

"The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction," Offen said in a statement. "We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 0.41
Market Cap: \$72.04 m

Share Information

Code: INNO
Listing: CSE
52 week **High** **Low**
0.42 **0.05**

Sector: Cannabis
Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).